HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Weider is now Schiff

This article was originally published in The Tan Sheet

Executive Summary

Weider Nutrition International formally changes name to Schiff Nutrition International following a shareholder vote of approval Oct. 25, the firm announces. "The Schiff brand is a recognized premium brand in the nutritional supplements arena, and it is appropriate that our new corporate name reflects our strategic commitment to growing the Schiff brand," President and CEO Bruce Wood said. The firm divested the Weider brand business last year, and its European subsidiary Haleko in June (1"The Tan Sheet" Aug. 23, 2004, p. 12 and 2"The Tan Sheet" June 27, 2005, In Brief). While the firm will start trading on the New York Stock exchange under the new name Nov. 1, WNI will remain the company's N.Y. Stock Exchange symbol....

You may also be interested in...



Follow The Weider: Analysts Glance Askance At Weider Brand Sale

Weider Nutrition International's sale of its namesake branded nutritionals to the company's majority stockholder is raising some concerns in the investment community

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS127390

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel